Expression, purification and preliminary pharmacological characterization of the Plasmodium falciparum membrane-bound pyrophosphatase type 1
PLOS One · 2025
DOI: 10.1371/journal.pone.0322756 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jianing Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Research Program in Molecular and Integrative Biosciences, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Plasmodium falciparum, Pyrophosphatases, Protozoan Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, Biotechnology and Biological Research Council, Suomen Farmaseuttinen Yhdistys.
Abstract (Originalsprache)
Membrane-bound pyrophosphatases are integral membrane proteins that catalyze the hydrolysis of pyrophosphate into orthophosphate, while simultaneously facilitating the pumping of protons and/or sodium ions. Since mPPases are absent in humans but play a critical role in the life cycle of protist parasite, they represent promising therapeutic targets. We successfully expressed the Plasmodium falciparum type 1 mPPase in the baculovirus/insect cell expression system and purified the protein, yielding 0.3 mg per liter cell culture. Various detergents were tested for solubilization, with the protein remaining active under all selected detergents. n -dodecyl-β-D-maltoside combined with cholesteryl hemisuccinate provided the highest solubility (88%). Finally, the PfPPase-VP1 was assayed against a set of fourteen antimalarial drugs, along with seven Thermotoga maritima mPPase inhibitors and fourteen compounds of unknown activity against mPPases. Only three compounds, all pyrazolo[1,5- a ]pyrimidine-based TmPPase inhibitors, retained micromolar IC 50 activity against PfPPase-VP1. The expression and purification of the PfPPase-VP1 will allow to conduct structural studies as well as to develop target-based screens, two steps necessary for the development of inhibitors to combat parasite disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Program in Molecular and Integrative Biosciences, University of Helsinki, Helsinki, Finland.
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Department of Chemistry, Faculty of Science, University of Helsinki, Helsinki, Finland.
ORCID-Profile: Jianing Liu, Niklas G Johansson, Loïc Dreano, Jari Yli-Kauhaluoma
Förderung
- Academy of Finland
- Biotechnology and Biological Research Council
- Suomen Farmaseuttinen Yhdistys
- Magnus Ehrnroothin Säätiö
- Swedish Cultural Foundation
- China Scholarship Council
Zitieren
APA
Liu, J., Vidilaseris, K., Johansson, N. G., Ribeiro, O., Dreano, L., Yli-Kauhaluoma, J., Xhaard, H., & Goldman, A. (2025). Expression, purification and preliminary pharmacological characterization of the Plasmodium falciparum membrane-bound pyrophosphatase type 1. PLOS One. https://doi.org/10.1371/journal.pone.0322756
Vancouver
Liu J, Vidilaseris K, Johansson NG, Ribeiro O, Dreano L, Yli-Kauhaluoma J, et al. Expression, purification and preliminary pharmacological characterization of the Plasmodium falciparum membrane-bound pyrophosphatase type 1. PLOS One. 2025. doi:10.1371/journal.pone.0322756
BibTeX
@article{Liu2025,
author = {Liu, Jianing and Vidilaseris, Keni and Johansson, Niklas G and Ribeiro, Orquidea and Dreano, Loïc and Yli-Kauhaluoma, Jari and Xhaard, Henri and Goldman, Adrian},
title = {Expression, purification and preliminary pharmacological characterization of the Plasmodium falciparum membrane-bound pyrophosphatase type 1},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0322756}
}
EUVIMED